What is Multiple Sclerosis? Gener al information

Similar documents
Multiple Sclerosis , The Patient Education Institute, Inc. nr Last reviewed: 04/17/2017 1

Multiple Sclerosis. Brain Spinal Cord. Peripheral Nerves

Progress in MS: Current and Emerging Therapies. Presented by: Dr. Kathryn Giles, MD MSc FRCPC Cambridge, Ontario, Canada

MULTIPLE SCLEROSIS INTRODUCTION OBJECTIVES. When the student has finished this module, he/she will be able to:

Multiple Sclerosis. What is multiple sclerosis? What is the cause? What are the symptoms?

Multiple Sclerosis. Biology 12 Nervous System Project

Multiple Sclerosis. What types of MS are there? 4 There are 4 types of MS.

MEDIA BACKGROUNDER. Multiple Sclerosis: A serious and unpredictable neurological disease

Frequently Asked Questions For persons with multiple sclerosis

Originally published December 2, Revisions and re-print November 2012.

Do you or did you have any family members who have been diagnosed with MS? Yes No I Don t Know. Yes identical Yes not identical No

Investor Update. Downloads. Services PDF. Basel, 17 July 2017

Relapses Matter A GUIDE TO REPORTING MULTIPLE SCLEROSIS SYMPTOMS

Get on with life, we ll see you. in 6 months. Living your life your way with MS

DOWNLOAD OR READ : MULTIPLE SCLEROSIS THE HISTORY OF A DISEASE PDF EBOOK EPUB MOBI

Understanding your Tecfidera. treatment. Information for patients who have been prescribed treatment with Tecfidera.

Mitzi Joi Williams, MD Neurologist MS Center of Atlanta Atlanta, GA

A Case Study: Multiple Sclerosis. Kayla Jensen February 2013

Media Release. Basel, 10 November 2017

Multiple sclerosis. Tünde Csépány MD. PhD

DISEASE-MODIFYING THERAPIES FOR MS

Anticipated Launches Q Q1 2019

Prof. Dimitrios Karussis Director of the Hadassah Center for MS

MULTIPLE SCLEROSIS - REVIEW AND UPDATE

The Impact of Multiple Sclerosis in the. James Bowen, MD Multiple Sclerosis Center

Roche s OCREVUS (ocrelizumab) approved in Switzerland for primary progressive and relapsing forms of multiple sclerosis

Disease-modifying therapies

Biology 3201 Nervous System # 7: Nervous System Disorders

AMPYRA (dalfampridine) extended release oral tablet Dalfampridine ER oral tablet

Multiple Sclerosis. By: Selena Fucci April 22, 2016

Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association

GILENYA (fingolimod) oral capsule

Medications to Slow Multiple Sclerosis Progression Multiple sclerosis disease-modifying medications

Pre-Return Visit Questionnaire for Multiple Sclerosis

MS Ireland s Opinion On The Introduction of Sativex

Multiple sclerosis. Tünde Csépány MD. PhD. 08. November 2017.

Biologics and Beyond: Treatment of Multiple Sclerosis. Rita Jebrin, PharmD, BCPS

TECFIDERA (dimethyl fumarate) oral capsule

Circle Yes or No Y N. [If no, skip to question 8.] 2. Has the patient been compliant with therapy as verified by the prescriber?

Le Hua, MD. Disclosures Teaching and Speaking: Teva Neurosciences, Genzyme, Novartis Advisory Board: Genzyme, EMD Serono

Advances in Progressive MS Research. Nicholas LaRocca, PhD

Social relationships, knowledge and adjustment to multiple sclerosis

Collaborative Consultation Interdisciplinary Treatment of Multiple Sclerosis

Multiple Sclerosis Diagnosis And Therapy

DOWNLOAD OR READ : MULTIPLE SCLEROSIS HOW I WON THE BATTLE PDF EBOOK EPUB MOBI

Pharmacy Management Drug Policy

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

RESEARCH/CLINICAL UPDATE

Advances in the Management of Multiple Sclerosis: A closer look at novel therapies. Disclosures

neurological rehabilitation multiple sclerosis

AUBMC Multiple Sclerosis Center

Regulatory Status FDA-approved indication: Tysabri is an integrin receptor antagonist indicated for treatment of (1):

GILENYA (fingolimod) oral capsule

DOWNLOAD OR READ : MULTIPLE SCLEROSIS PDF EBOOK EPUB MOBI

News Release. March 29, 2019

Choices. Disease modifying treatments. Read me

387

Positive Phase III results for Roche s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine

Innovation immunomodulatory treatment case study of men diagnosed with relapsing-remitting multiple sclerosis (MS)

Certificate of Merit in Disorders of the Body Lesson 2: Epilepsy, Diabetes and Multiple Sclerosis

ONE PILL, ONCE A DAY GET TO KNOW AUBAGIO. Ask your doctor if AUBAGIO may be right for you. Patient Portrayal

natalizumab (Tysabri )

Neurological Assessment for Multiple Sclerosis and Extended Disability Scale Score

MileStones 2010 SPONSORSHIP OPPORTUNITIES

Regulatory Status FDA-approved indication: Tysabri is an integrin receptor antagonist indicated for treatment of:

While MS sometimes causes severe disability, it is only rarely fatal and most people with MS have a normal life expectancy.

Rapid Recovery Hyperbarics 9439 Archibald Ave. Suite 104 Rancho Cucamonga CA,

SUBHAN ALLAH US/CANADIAN PHARMACY EXAMS EDNAN UNDERSTANDING MULTIPLE SCLEROSIS (MS) COPY RIGHT PROTECTED Page 1

MDWISE PRIOR AUTHORIZATION CRITERIA TYSABRI (natalizumab): 300mg/15mL single use vial

Dr. Terry Wahls Interview pitch. Bio

History of Present Condition

The Complete Guide To Multiple Sclerosis Symptoms: How To Manage Multiple Sclerosis, MS Pain And Control MS Disease Naturally By Benjamin Weber

Mediators of Employment Status and Depression in Multiple Sclerosis

Overview 12/8/2008. Simplifying Neurology for critical illness claims. Multiple Sclerosis. Basics Advances in diagnosis and treatment.

APPENDIX D SASKATCHEWAN MS DRUGS PROGRAM

Updates to the Alberta Human Services Drug Benefit Supplement

PROGRESSIVE MULTIPLE SCLEROSIS

presents How to S.E.A.R.C.H. for the Right MS Therapy for You! G Live Webinar October 19, 2016

AUBAGIO (teriflunomide) oral tablet

Understanding Stroke

Cancer Survivorship NEURO-ONCOLOGY PATIENT SURVIVORSHIP PLAN. Resources and Tools for the Multidisciplinary Team

KEEPING IN TOUCH WITH THE NORTHUMBERLAND CHAPTER MS SOCIETY

DRG STIMULATION FOR CHRONIC PAIN FOCUS ON YOUR LIFE NOT YOUR PAIN

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

MODULE 5: Working with the Student with MS

TREATING MULTIPLE SCLEROSIS The Current Disease Modifying Therapies Beverly Gilder, M.D. Blue Sky Neurology MS Center

Optic neuritis. Information for patients Ophthalmology

Clinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date:

Prior Authorization. Drug Name (select from list of drugs shown) Gilenya (fingolomid) Quantity Frequency Strength. Physician Name:

Expectation of a Rare Event. Laura Meyerson, Ph.D Midwest Biopharmaceutical Statistics Workshop Ball State University Muncie, IN

Aurora Doctor Answers the President s Call

The Role of MRI in Multiple Sclerosis

CHRONIC CONDITIONS FYI

Choices. Types of MS. Read me

CHAIR SUMMIT 7TH ANNUAL #CHAIR2014. Master Class for Neuroscience Professional Development. September 11 13, Westin Tampa Harbour Island

Guideline for the use of beta-interferons in patients with multiple sclerosis a South African proposal

Media Release. Basel 12 January 2018

Committee Approval Date: December 12, 2014 Next Review Date: December 2015

PATIENT ENTRANCE FORM

Transcription:

What is Multiple Sclerosis? Gener al information Kim, diagnosed in 1986

What is MS? Multiple sclerosis (or MS) is a chronic, often disabling disease that attacks the central nervous system (brain and spinal cord). Symptoms may be mild, such as numbness in the limbs, or severe, such as paralysis or loss of vision. The progress, severity, and specific symptoms of MS vary among individuals and are unpredictable. Today, new treatments and advances in research are giving new hope to people who are affected by the disease. MS is thought to be an autoimmune disease. The body s own defense system attacks myelin, the fatty substance that surrounds and protects the nerve fibers of the brain, optic nerves, and spinal cord (the central nervous system). Beverly, diagnosed in 2001

The damaged myelin may form scar tissue (sclerosis). Often the nerve fiber is also damaged. When any part of the myelin sheath or nerve fiber is damaged or destroyed, nerve impulses traveling to and from the brain are distorted or interrupted. MS is not a fatal disease. Individuals with MS have near-normal life expectancies. Most people with MS learn to cope with the disease and are able to live productive lives. What are its symptoms? The symptoms of MS may include tingling, numbness, painful sensations, slurred speech, and blurred or double vision. Some people experience muscle weakness, poor balance, poor coordination, muscle tightness or spasticity, tremors, or paralysis, which may be temporary or permanent. Problems with bladder, bowel, or sexual function are common. Fatigue is a major concern for many. MS can cause forgetfulness or difficulty concentrating. It can also cause mood swings and may make people more susceptible to depression. Symptoms may come and go, appear in any combination, and be mild, moderate, or severe.

Can MS be treated? Yes. Today, there are seven diseasemodifying medications approved by the Food and Drug Administration (FDA) to treat MS. Five of them Avonex, Betaseron, Copaxone, Extavia, and Rebif are immunomodulating drugs (meaning that they modulate or alter the immune system) that are given by injection. These drugs have been shown to be effective in modifying the natural course of relapsing forms of MS. The National MS Society recommends that treatment with one of these disease modifiers be considered as soon as possible following a confirmed diagnosis of MS with a relapsing course. Treatment with a disease-modifying drug may be recommended even before an individual is definitely diagnosed, if the person experienced one attack (also called a relapse or exacerbation) and has evidence of MS lesions as seen by MRI scanning. Tysabri, another immunomodulating drug approved by the FDA, is delivered by infusion. It is recommended for patients who have an inadequate response to, or are unable to tolerate, other MS therapies.

The seventh drug, Novantrone, is a powerful immune system suppressor shown to be effective in slowing down MS that is rapidly worsening or becoming progressive. Novantrone is delivered by infusion. Steroids may be used to shorten acute attacks. Many other medications and combinations, including oral therapies, are in various stages of clinical trials or are under review by the FDA, and researchers are hopeful that more treatments for MS will be available in the near future. Please check nationalmssociety.org for updates. There are also many medications to relieve or moderate MS symptoms such as spasticity, bowel and urinary distress, pain, fatigue, or depression, including one MS-specific symptom management medication (Ampyra ) recently approved by the FDA to improve walking. Physical therapy, exercise, vocational and cognitive rehabilitation, attention to diet, adequate rest, and counseling are often valuable for maintaining independence and quality of life. Prompt management of symptoms is vital and should be discussed with a knowledgeable physician.

AJ, diagnosed in 2000 Who gets MS? An estimated 400,000 Americans have MS. Most are diagnosed between the ages of 20 and 50, and about two thirds are women. The disease is more frequently found among people raised in colder climates. Studies indicate that genetic factors make certain individuals susceptible to the disease, but there is no evidence that MS is directly inherited. What happens in MS? MS is an unpredictable disease. Symptoms vary greatly from person to person and vary over time in the same person.

Periods of active MS symptoms are called attacks, exacerbations, or relapses. These can be followed by quiet periods called remissions. The disease ranges from very mild and intermittent to steadily progressive. Some people have few attacks and little, if any, accumulation of disability over time. At diagnosis, most people have relapsingremitting disease. This means they have attacks followed by periods of partial or total remission that may last months or even years. Others experience a progressive disease course with steadily worsening symptoms. The disease may worsen steadily from the onset (primary-progressive MS) or may become progressive after a relapsing-remitting course (secondaryprogressive MS). Because MS affects individuals so differently, it is difficult to make generalizations about disability. Statistics suggest that 2 out of 3 people with MS remain able to walk over their lifetime, though many of them will need a cane or other assistive device. Some will choose to use a scooter or wheelchair to conserve energy. Others will require a wheelchair to maintain mobility. The disease-modifying treatments, which have been in use only since the 1990s, may favorably alter this projection.

Is MS easily diagnosed? MS is not always easy to diagnose because symptoms may come and go. In addition, other diseases of the central nervous system have some of the same symptoms. No single neurological or laboratory test can confirm or rule out MS. Medical imaging, particularly MRI (magnetic resonance imaging), helps to clarify the diagnosis. A conclusive or definitive diagnosis requires evidence of multiple patches of scar tissue in different parts of the central nervous system and evidence of at least two separate attacks of the disease. A definitive diagnosis can take several months. Sometimes it takes years. Can MS be cured? The answer is no not yet. The cause and the cure of MS are the subject of intensive worldwide research. Over 300 research grants and fellowships are funded by the National MS Society each year. Knowledge about MS is expanding and many clinical trials are in progress. For information: 1-800-344-4867 nationalmssociety.org 2010 National MS Society. All rights reserved. BR 3009 4/10

Join the Movement The National MS Society Information, local referrals, publications, programs, and volunteer opportunities are available from the National Multiple Sclerosis Society and our 50-state network of chapters. To reach the chapter nearest you, call 1-800-344-4867 or visit nationalmssociety.org. The Society is comprised of people who want to do something about MS now people with MS, their family members, concerned friends, neighbors, healthcare professionals, volunteers and staff. As the world s largest private funder of MS research, the Society supports local, state, and national advocacy programs, and serves as the voice for people with MS. Ampyra is a trademark of Acorda Therapeutics. Avonex is a registered trademark of Biogen Idec. Betaseron is a registered trademark of Bayer Schering Pharma Aktiengesellschaft. Copaxone is a registered trademark of Teva Pharmaceutical Industries Ltd. Extavia is a registered trademark of Novartis AG. Novantrone is a registered trademark of Immunex Corp. Rebif is a registered trademark of Ares Trading S.A. Tysabri is a registered trademark of Elan Pharmaceuticals, Inc.